Trial Profile
CLINICAL AND TRASLATIONAL PHASE II STUDY OF LIPOSOMAL DOXORUBICIN PLUS DOCETAXEL AND TRASTUZUMAB WITH METFORMIN AS PRIMARY SYSTEMIC THERAPY FOR OPERABLE AND LOCALLY ADVANCED HER2 POSITIVE BREAST CANCER.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 10 Mar 2015
Price :
$35
*
At a glance
- Drugs Doxorubicin liposomal (Primary) ; Docetaxel; F-18 fluorothymidine; Metformin; Trastuzumab
- Indications Advanced breast cancer; HER2 positive breast cancer; Male breast cancer
- Focus Therapeutic Use
- Acronyms met-HEReMYTA
- 10 Mar 2015 New trial record